Skip to main content

Table 2 Routine laboratory tests, vital signs, and body mass index before, during, and after roxadustat treatment

From: Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

  2019 2020
May Jun. Jul. Aug. Sept. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sept.
Treatment for anemia DARBE DARBE DARBE DARBE DARBE DARBE DARBE DARBE DARBE ROXAD ROXAD ROXAD ROXAD DARBE DARBE DARBE DARBE
Hemoglobin (g/dL) 9.4 9.5 9.8 10.6 9.5 8.3 9.3 9.2 9.0 8.5 8.9 9.2 8.8 7.9 8.2 7.2 7.5
TC (mg/dL) 126 124 115 113 120 110 123 129 127 76 67 64 52 67 122 111 126
Non-HDL-C (mg/dL) 88 85 87 91 92 49 47 33 43 85 80 92
HDL-C (mg/dL) 30 30 33 32 36 18 17 19 24 37 31 34
AST (IU/L) 18 17 16 18 17 17 22 19 7 18 19 20 17 19 18 17 17
ALT (IU/L) 8 8 8 8 8 8 9 8 8 9 8 10 9 9 7 7 7
Serum albumin (g/dL) 3.6 3.5 3.3 3.4 3.4 3.3 3.5 3.5 3.4 3.0 3.1 3.4 3.4 3.2 3.5 3.2 3.4
BUN (mg/dL) 36.3 54.3 52.2 58.0 47.8 61.2 55.5 60.5 48.6 57.4 48.3 51.6 50.9 40.8 39.4 43.8 54.2
Creatinine (mg/dL) 8.9 8.9 9.7 9.8 9.6 9.7 9.6 9.2 9.5 8.2 8.1 7.6 7.2 6.5 7.0 8.0 8.9
CRP (mg/dL) 0.27 0.68 0.22 0.13 0.37 0.38 0.28 0.19 0.24 0.43 0.30 0.25 0.23 0.28 0.21 0.35 0.15
Ferritin (ng/ml) 120.4 420.3 339.7 361.8 324.0 219.3 193.8 215.6 238.2 178.7 173.8
TSAT (%) 27.5 24.0 21.8 30.2 30.4 45.5 32.3 44.5 50.9 56.2 82.4 41.8 57.1 39.3 40.8 26.8 28.3
BMI (kg/m2) 22.1 22.0 21.9 21.9 22.1 22.1 22.2 22.4 22.4 22.4 22.2 21.9 21.9 21.8 21.6 21.8 21.5
Pulse rate (ppm) 64.1 69.6 65.5 67.4 69.5 65.4 68.5 67.1 67.4 71.8 71.7 73.4 69.9 68.6 67.5 65.6 63.8
SBP (mmHg) 146.3 153.3 149.6 139.7 140.4 138.7 147.2 141.2 144.5 150.3 162.7 160.0 153.8 151.4 154.0 151.2 148.0
DBP (mmHg) 70.0 76.2 72.3 68.5 69.5 69.3 71.2 66.6 69.0 74.4 78.4 73.1 70.2 71.4 71.6 71.5 68.2
  1. Treatment for renal anemia was switched from darbepoetin alfa to roxadustat. The treatment with roxadustat was done from February 2 to June 12, 2020. Measurements were done in the last week of each month. Note the reductions of TC, Non-HDL-C, and HDL-C levels during roxadustat treatment.
  2. Abbreviations: DARBE darbepoetin alfa; ROXAD roxadustat; TC total cholesterol; Non-HDL-C non-high-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; AST aspartate aminotransferase; ALTalanine aminotransferase; BUN blood urea nitrogen; CRP C-reactive protein; TSAT transferrin saturation; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure